What does Serum Glycosylated Apolipoprotein J mean in a heart attack?-----Correlation of serum glycosylated apolipoprotein J with acute myocardial infarction

Background There are few myocardial damage markers that could be used to diagnose acute myocardial infarction(AMI) or assess its severity, especially glycosylated apolipoprotein J(ApoJ-Glyc) has demonstrated superiority in cardiomyocytes and animal STEMI models in the early stages of myocardial ischemia(MI). We aimed to excavate the potential role of ApoJ-Glyc as a protein marker in the pathogenesis of AMI in humans and its added value in the evolution of the disease. Methods and Results ELISA was used to determine the serum concentration of ApoJ-Glyc in 163 patients enrolled by the criteria. Statistical analysis could used to discuss the relationship between ApoJ-Glyc and AMI. Compared to control groups, serum ApoJ-Glyc levels decreased by 36% and 37% in early AMI patients and AMI patients, respectively (P<0.0001), showing a higher discriminant value for early diagnosis and diagnosis of AMI [area under the curve (AUC) : 0.871 and 0.886, P< 0.0001]. For the first time, we demonstrated that ApoJ-Glyc was not statistically significant in the comparative difference between NSTEMI and STEMI groups (P> 0.05). Patients with gradually declining ApoJ-Glyc had a higher Grace Risk Scores. Subsequent studies have also demonstrated that more MACCE did occur with a 6-month follow-up(P<0.05). Conclusions ApoJ-Glyc which serve as an alarm bell for the detection of early ischaemia, may be a new biomarker for AMI. ApoJ-Glyc can assess the severity of myocardial infarction. The continuous decrease of serum ApoJ-Glyc suggests an increase in the risk of post-AMI ischaemia and the onset of unpredictable MACCE. ![Figure][1] ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by National Natural Science Foundation of China (No.82200503), Key Research and Development Program of Shandong Province (No. 2019GSF108142)and National Natural Science Foundation of Shandong Province(No. ZR2020MH185 and ZR2022QH237) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by Ethics Committee of Yantai Yuhuangding Hospital (NO.:2023-254; approved May 29, 2023; ?Correlation of serum glycosylated apolipoprotein J with acute myocardial infarction?). The study protocol conforms to the ethical standards of the responsible committee on human experimentation (institutional or regional) and the 1975 Declaration of Helsinki. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The data underlying this article will be shared on reasonable request to the corresponding author. * ApoJ-Glyc : glycosylated apolipoprotein J [1]: pending:yes